SYNDAX PHARMACEUTICALS INC (SNDX)
US87164F1057 - Common Stock
SNDX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 586 industry peers in the Biotechnology industry. The financial health of SNDX is average, but there are quite some concerns on its profitability. SNDX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SNDX had negative earnings in the past year.
SNDX had a negative operating cash flow in the past year.
SNDX had negative earnings in 4 of the past 5 years.
SNDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -44.30%, SNDX perfoms like the industry average, outperforming 53.68% of the companies in the same industry.
With a decent Return On Equity value of -48.91%, SNDX is doing good in the industry, outperforming 67.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.3% | ||
| ROE | -48.91% | ||
| ROIC | N/A |
ROA(3y)-19.55%
ROA(5y)-34.5%
ROE(3y)-21.21%
ROE(5y)-54.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SNDX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SNDX has been increased compared to 5 years ago.
The debt/assets ratio for SNDX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 17.01 indicates that SNDX is not in any danger for bankruptcy at the moment.
SNDX has a Altman-Z score of 17.01. This is amongst the best in the industry. SNDX outperforms 90.60% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that SNDX is not too dependend on debt financing.
SNDX has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.01 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 8.93 indicates that SNDX has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.93, SNDX is doing good in the industry, outperforming 73.50% of the companies in the same industry.
SNDX has a Quick Ratio of 8.93. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
SNDX has a better Quick ratio (8.93) than 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.93 | ||
| Quick Ratio | 8.93 |
3. Growth
3.1 Past
SNDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.61%.
EPS 1Y (TTM)-33.61%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-44.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 14.09% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-33.17%
EPS Next 2Y0.03%
EPS Next 3Y8.25%
EPS Next 5Y14.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.03%
EPS Next 3Y8.25%
5. Dividend
5.1 Amount
No dividends for SNDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYNDAX PHARMACEUTICALS INC
NASDAQ:SNDX (5/17/2024, 8:28:33 PM)
After market: 20.29 0 (0%)20.29
-0.63 (-3.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.72B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.3% | ||
| ROE | -48.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.93 | ||
| Quick Ratio | 8.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-33.61%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-33.17%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y